Conditions: Leukemia
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 46
Healthy volunteers: no

Brief summary:
To determine the long term safety and tolerability of dasatinib exposure in subjects previously treated in CA180-002.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Dasatinib
Intervention descriptions: intervention 1: Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules:

* 5 days on, 2 days off
* 6 days on, 1 day off
* Continuous daily dosing

Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study

Protocol document: